Vigabatrin (Sabril) vs Vigabatrin (Vigafyde)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA transaminase (GABA-T) · full Epilepsy pipeline

Vigabatrin (Sabril)

Marketed by Lundbeck LLC and partners

Approved in Epilepsysmall molecule
Partial signal

NCT02849457 · Phase 2 · completed

The study enrolled 84 infants, with 56 entering the randomized comparison of early vigabatrin versus matching placebo/delayed vigabatrin; participants, caregivers, and investigators were blinded. The primary clinical-function endpoint, the 24-month Bayley cognitive score, was not met: the adjusted comparison was not statistically significant (p=0.8681), so the results provide well-controlled but unclear evidence of benefit.

Reported efficacy

Cognitive Assessment Scores and Developmental Impact (24 months): Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) (missed)

Result source: NCT02849457

Vigabatrin (Vigafyde)

Marketed by Bora Pharmaceuticals Co., Ltd. and partners

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointVigabatrin (Sabril)Vigabatrin (Vigafyde)
Seizure frequency, % change—Not reported—Not reported
50% responder rate—Not reported—Not reported
Seizure freedom—Not reported—Not reported

Seizure frequency, % change

Vigabatrin (Sabril)
—Not reported
Vigabatrin (Vigafyde)
—Not reported

50% responder rate

Vigabatrin (Sabril)
—Not reported
Vigabatrin (Vigafyde)
—Not reported

Seizure freedom

Vigabatrin (Sabril)
—Not reported
Vigabatrin (Vigafyde)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Vigabatrin (Vigafyde): no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Vigabatrin (Sabril): 3 of 4 rows · Vigabatrin (Vigafyde): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVigabatrin (Sabril)
Dropout rate
—Early Post-randomizationa
NCT02849457 · Phase 2
show 4 more results
—Early Vigabatrin
NCT02849457 · Phase 2
—Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
—Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
0%
NCT04772547 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Early Post-randomizationa
NCT02849457 · Phase 2
show 4 more results
—Early Vigabatrin
NCT02849457 · Phase 2
—Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
—Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
—
NCT04772547 · Phase 2 · registry result, not featured evidence
Serious AEs
51.7%Early Post-randomizationa
NCT02849457 · Phase 2
show 4 more results
—Early Vigabatrin
NCT02849457 · Phase 2
—Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
50%Watchful Waiting (Open Label Vigab
NCT02849457 · Phase 2
0%
NCT04772547 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
infections and infestations 27.6% (placebo 25.9%)
respiratory, thoracic and mediastinal disorders 24.1% (placebo 14.8%)
general disorders 13.8% (placebo 11.1%)
NCT02849457 · Phase 2
show 1 more result
blood and lymphatic system disorders 25% (placebo 0%)
general disorders 25% (placebo 11.1%)
infections and infestations 25% (placebo 25.9%)
NCT02849457 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vigabatrin (Sabril)

Cognitive Development 80.9 vs 83.9 placebo score @ 104wk
absolute value · score
NCT02849457 · Phase 2
show 1 more result
85 vs 83.9 placebo score @ 104wk
NCT02849457 · Phase 2
Seizure Occurrence 69% (n=29) vs 73.1% (n=26) placebo @ 104wk
event count · % of participants
NCT02849457 · Phase 2 · converted to % from 20 Participants as posted
Time to First Seizure 9.47 vs 2.77 placebo months
time to event · months
NCT02849457 · Phase 2
Drug Resistant Epilepsy 48.3% (n=29) vs 58.3% (n=24) placebo @ 104wk
event count · % of participants
NCT02849457 · Phase 2 · converted to % from 14 Participants as posted
Vineland ABC 86 vs 86.9 placebo score @ 52wk
absolute value · score
NCT02849457 · Phase 2
show 5 more results
86.3 vs 86.9 placebo score @ 52wk
NCT02849457 · Phase 2
84.9 vs 90.6 placebo score @ 104wk
NCT02849457 · Phase 2
85.3 vs 90.6 placebo score @ 104wk
NCT02849457 · Phase 2
78.6 vs 86.2 placebo score @ 156wk
NCT02849457 · Phase 2
76.8 vs 86.2 placebo score @ 156wk
NCT02849457 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Vigabatrin (Sabril)'s landscape · Vigabatrin (Vigafyde)'s landscape